| LEW.1F |
post-insult time to onset of experimental arthritis |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
10 |
17.0 |
d |
1.26 |
4.0 |
in vivo visual assessment |
0.0 |
0 |
69669 |
1159 |
| DXE2/Ztm |
percentage of study population developing chronic experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
24 |
30.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69682 |
1159 |
| DA/ZtmRhd |
percentage of study population developing experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
17 |
100.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69663 |
1159 |
| DXE1/Ztm |
percentage of study population developing experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
20 |
70.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69665 |
1159 |
| DXE1/Ztm |
percentage of study population developing experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
20 |
10.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69681 |
1159 |
| LEW.1F |
percentage of study population developing experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
10 |
100.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69661 |
1159 |
| E3/ZtmRhd |
post-insult time to onset of experimental arthritis |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
23 |
38.0 |
d |
1.25 |
6.0 |
in vivo visual assessment |
0.0 |
0 |
69672 |
1159 |
| DXE2/Ztm |
post-insult time to onset of experimental arthritis |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
24 |
72.0 |
d |
6.94 |
34.0 |
in vivo visual assessment |
0.0 |
0 |
69674 |
1159 |
| DXE3/Ztm |
post-insult time to onset of experimental arthritis |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
20 |
32.0 |
d |
3.35 |
15.0 |
in vivo visual assessment |
0.0 |
0 |
69675 |
1159 |
| E3/ZtmRhd |
percentage of study population developing chronic experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
23 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69680 |
1159 |
| DXE1/Ztm |
post-insult time to onset of experimental arthritis |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
20 |
31.0 |
d |
4.7 |
21.0 |
in vivo visual assessment |
0.0 |
0 |
69673 |
1159 |
| DXE3/Ztm |
percentage of study population developing experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
20 |
10.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69667 |
1159 |
| LEW.1N |
post-insult time to onset of experimental arthritis |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
11 |
21.0 |
d |
2.11 |
7.0 |
in vivo visual assessment |
0.0 |
0 |
69670 |
1159 |
| LEW.1F |
percentage of study population developing chronic experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
10 |
100.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69677 |
1159 |
| DA/ZtmRhd |
post-insult time to onset of experimental arthritis |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
17 |
14.0 |
d |
0.49 |
2.0 |
in vivo visual assessment |
0.0 |
0 |
69671 |
1159 |
| LEW/Han |
percentage of study population developing chronic experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
11 |
82.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69676 |
1159 |
| DA/ZtmRhd |
percentage of study population developing chronic experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
17 |
100.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69679 |
1159 |
| E3/ZtmRhd |
percentage of study population developing experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
23 |
9.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69664 |
1159 |
| LEW.1N |
percentage of study population developing experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
11 |
64.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69662 |
1159 |
| DXE2/Ztm |
percentage of study population developing experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
24 |
33.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69666 |
1159 |
| LEW.1N |
percentage of study population developing chronic experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
11 |
54.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69678 |
1159 |
| DXE3/Ztm |
percentage of study population developing chronic experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
20 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69683 |
1159 |
| LEW/Han |
percentage of study population developing experimental arthritis during a period of time |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
11 |
82.0 |
% |
|
|
in vivo visual assessment |
0.0 |
0 |
69660 |
1159 |
| LEW/Han |
post-insult time to onset of experimental arthritis |
pristane (150 ul) |
Vingsbo C, et al., Am J Pathol 1996 Nov;149(5):1675-83 |
joint integrity trait |
both |
56 days-98 days |
11 |
23.0 |
d |
3.02 |
10.0 |
in vivo visual assessment |
0.0 |
0 |
69668 |
1159 |
